Category - Developments

Developments

Pulmatrix opens three Phase 2 clinical trial sites for inhaled anti-fungal

Pulmatrix (NASDAQ:PULM) activated three U.S. sites for its Phase 2 clinical trial of pulmazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. The primary objective of the...

July 9, 2019

Developments

Tilray expands European team with five senior appointments

Tilray (NASDAQ:TLRY) welcomed five individuals to its leadership team to support the company’s aggressive European and international expansion strategy. Tilray appointed Arne Wilkens as VP business expansion; José...

July 8, 2019

Developments

Bellicum Pharma rivo-cel hits primary endpoint in pivotal trial

Bellicum Pharmaceuticals’ (NASDAQ:BLCM) registrational trial of rivo-cel achieved its primary endpoint of event-free survival when the drug was administered to patients receiving stem cell transplants.

July 8, 2019

Developments

Prevail Therapeutics gets FDA fast track designation for Parkinson’s disease gene therapy

Prevail Therapeutics (NASDAQ:PRVL) received FDA fast track designation for PR001, a gene therapy candidate for the treatment of Parkinson’s disease (PD).

July 8, 2019

Developments

Tyme Technologies reports new Phase 2 data for pancreatic cancer drug candidate

Tyme Technologies (NASDAQ:TYME) reported updated results from its Phase 2 trial of SM-88 in patients with pancreatic cancer.

July 5, 2019

Developments

FDA approves Karyopharm Therapeutics XPOVIO for multiple myeloma

The FDA approved Karyopharm Therapeutics (NASDAQ:KPTI) XPOVIO, in combination with dexamethasone, for the treatment of relapsed or refractory multiple myeloma (RRMM).

July 3, 2019

Developments

Ovid Therapeutics OV101 granted orphan designation in Europe

Ovid Therapeutics (NASDAQ: PTI) reported that, following a positive opinion from the European Medicines Agency, the European Commission granted OV101 orphan drug designation for the treatment of Angelman syndrome.

July 3, 2019

Developments

Zenabis arranges $30-million non-dilutive financing in supply pact with Tilray

Zenabis Global (TSX:ZENA) entered into an agreement with High Park Holdings, a wholly-owned unit of Tilray (NASDAQ:TLRY), for High Park to advance $30- million (Canadian) to Zenabis in return for a supply of dried...

July 2, 2019

Developments

vTv Therapeutics starts Phase 2 trial in patients with AD and T2D

vTv Therapeutics (NASDAQ:VTVT) initiated a Phase 2 trial of azeliragon in patients with Alzheimer’s disease (AD) and Type 2 diabetes (T2D).

June 29, 2019

Developments

Arcturus Therapeutics gets FDA orphan drug designation for ARCT-810

Arcturus Therapeutics (NASDAQ:ARCT) received FDA orphan drug designation for ARCT-810 for the treatment of ornithine transcarbamylase (OTC) deficiency.

June 29, 2019

Category - Developments

Pulmatrix opens three Phase 2 clinical trial sites for inhaled anti-fungal

Tilray expands European team with five senior appointments

Bellicum Pharma rivo-cel hits primary endpoint in pivotal trial

Prevail Therapeutics gets FDA fast track designation for Parkinson’s disease gene therapy

Tyme Technologies reports new Phase 2 data for pancreatic cancer drug candidate

FDA approves Karyopharm Therapeutics XPOVIO for multiple myeloma

Ovid Therapeutics OV101 granted orphan designation in Europe

Zenabis arranges $30-million non-dilutive financing in supply pact with Tilray

vTv Therapeutics starts Phase 2 trial in patients with AD and T2D

Arcturus Therapeutics gets FDA orphan drug designation for ARCT-810

General

More